GREAT is a research collaboration to develop an innovative AIDS vaccine that addresses the broad variability of HIV and would be suitable for use around the world.
European and African researchers from eight different organizations have teamed up to advance a HIV vaccine candidate, HIVconsvX, designed to prevent infection throughout the world. The novel vaccine construct is designed to address the variability of HIV-1, which presents one of the greatest challenges to introducing an effective vaccine. Such a vaccine is critical to ending the HIV/AIDS epidemic.
Professor Tomáš Hanke of the Jenner Institute at the University of Oxford is leading the programme to evaluate the vaccine candidate in Europe and Africa, in collaboration with Imperial College London, IAVI, KAVI-Institute for Clinical Research, KEMRI-Wellcome Trust Research Programme, the Medical Research Council at the Uganda Virus Research Institute on AIDS, the UVRI-IAVI HIV Vaccine Program in Uganda and the Zambia Emory HIV Research Project. The programme is supported by the European & Developing Countries Clinical Trials Partnership (EDCTP).